High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions

2014 ◽  
Vol 50 (4) ◽  
pp. 852-861 ◽  
Author(s):  
Katharina Grupp ◽  
Julia Wilking ◽  
Kristina Prien ◽  
Claudia Hube-Magg ◽  
Hüseyin Sirma ◽  
...  
Medicine ◽  
2019 ◽  
Vol 98 (29) ◽  
pp. e16193 ◽  
Author(s):  
Jing-bo Liu ◽  
Yong-ji Yan ◽  
Jing Shi ◽  
Ya-bing Wu ◽  
Yan-feng Li ◽  
...  

2006 ◽  
Vol 24 (19) ◽  
pp. 3081-3088 ◽  
Author(s):  
Anna C. Ferrari ◽  
Nelson N. Stone ◽  
Ralf Kurek ◽  
Elizabeth Mulligan ◽  
Roy McGregor ◽  
...  

Purpose Thirty percent of patients treated with curative intent for localized prostate cancer (PC) experience biochemical recurrence (BCR) with rising serum prostate-specific antigen (sPSA), and of these, approximately 50% succumb to progressive disease. More discriminatory staging procedures are needed to identify occult micrometastases that spawn BCR. Patients and Methods PSA mRNA copies in pathologically normal pelvic lymph nodes (N0-PLN) from 341 localized PC patients were quantified by real-time reverse-transcriptase polymerase chain reaction. Based on comparisons with normal lymph nodes and PLN with metastases and on normalization to 5 × 106 glyceraldehyde-3′-phosphate dehydrogenase mRNA copies, normalized PSA copies (PSA-N) and a threshold of PSA-N 100 or more were selected for continuous and categorical multivariate analyses of biochemical failure-free survival (BFFS) compared with established risk factors. Results At median follow-up of 4 years, the BFFS of patients with PSA-N 100 or more versus PSA-N less than 100 was 55% and 77% (P = .0002), respectively. The effect was greatest for sPSA greater than 20 ng/mL, 25% versus 60% (P = .014), Gleason score 8 or higher, 21% versus 66% (P = .0002), stage T3c, 18% versus 64% (P = .001), and high-risk group (50% v 72%; P = .05). By continuous analysis PSA-N was an independent prognostic marker for BCR (P = .049) with a hazard ratio of 1.25 (95% CI, 1.001 to 1.57). By categorical analysis, PSA-N 100 or more was an independent variable (P = .021) with a relative risk of 1.98 (95% CI, 1.11 to 3.55) for BCR compared with PSA-N less than 100. Conclusion PSA-N 100 or more is a new, independent molecular staging criterion for localized PC that identifies high-risk group patients with clinically relevant occult micrometastases in N0-PLN, who may benefit from additional therapy to prevent BCR.


2008 ◽  
Vol 54 (5) ◽  
pp. 1097-1108 ◽  
Author(s):  
Florian R. Fritzsche ◽  
Monika Jung ◽  
Angelika Tölle ◽  
Peter Wild ◽  
Arndt Hartmann ◽  
...  

1999 ◽  
Vol 36 (3) ◽  
pp. 191-196 ◽  
Author(s):  
Christian Palmberg ◽  
Pasi Koivisto ◽  
Tapio Visakorpi ◽  
Teuvo L.J. Tammela

Oncotarget ◽  
2017 ◽  
Vol 8 (2) ◽  
pp. 3761-3761
Author(s):  
Martina Kluth ◽  
Ramin Ahrary ◽  
Claudia Hube-Magg ◽  
Malik Ahmed ◽  
Heinke Volta ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document